Evidence map›Paper›PMID 33233502›Full record

ReviewInternational journal of molecular sciences2020

Effects of Ketone Bodies on Brain Metabolism and Function in Neurodegenerative Diseases.

Nicole Jacqueline Jensen, Helena Zander Wodschow, Malin Nilsson, Jørgen Rungby

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 236 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
236citing papers in PubMed, 2 pooled it
22.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

236 citing papers in PubMed, 2 syntheses or guidelines pooled it, 409 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Cerebral fuels within the first week of life in very preterm infants: a cohort study.Archives of disease in childhood. Fetal and neonatal edition · 2026
    Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. AAV-mediated FGF21 gene therapy promotes health span extension by whole-body tissue-specific adaptations.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

176 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Nicole Jacqueline JensenDepartment of Endocrinology, Bispebjerg University Hospital, 2400 Copenhagen, Denmark.ORCID 0000-0002-1202-4056
Helena Zander WodschowDepartment of Endocrinology, Bispebjerg University Hospital, 2400 Copenhagen, Denmark.
Malin NilssonDepartment of Endocrinology, Bispebjerg University Hospital, 2400 Copenhagen, Denmark.
Jørgen RungbyDepartment of Endocrinology, Bispebjerg University Hospital, 2400 Copenhagen, Denmark.ORCID 0000-0002-5207-623X
Bispebjerg Hospital · DKFrederiksberg Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Under normal physiological conditions the brain primarily utilizes glucose for ATP generation. However, in situations where glucose is sparse, e.g., during prolonged fasting, ketone bodies become an important energy source for the brain. The brain's utilization of ketones seems to depend mainly on the concentration in the blood, thus many dietary approaches such as ketogenic diets, ingestion of ketogenic medium-chain fatty acids or exogenous ketones, facilitate significant changes in the brain's metabolism. Therefore, these approaches may ameliorate the energy crisis in neurodegenerative diseases, which are characterized by a deterioration of the brain's glucose metabolism, providing a therapeutic advantage in these diseases. Most clinical studies examining the neuroprotective role of ketone bodies have been conducted in patients with Alzheimer's disease, where brain imaging studies support the notion of enhancing brain energy metabolism with ketones. Likewise, a few studies show modest functional improvements in patients with Parkinson's disease and cognitive benefits in patients with-or at risk of-Alzheimer's disease after ketogenic interventions. Here, we summarize current knowledge on how ketogenic interventions support brain metabolism and discuss the therapeutic role of ketones in neurodegenerative disease, emphasizing clinical data.

Indexed as

Adenosine TriphosphateAlzheimer DiseaseAnimalsBrainDiet, KetogenicFastingGlucoseGlycolysisHumansKetone BodiesLiverNeurogliaNeuronsNeuroprotective AgentsParkinson DiseaseRodentiaAdenosine TriphosphateGlucoseKetone BodiesNeuroprotective Agentsastrocytescerebral metabolismcognitionketogenic dietketone bodiesketone supplementsneurodegenerationSGLT-2 inhibitors

Identifiers

PMID33233502
PMCPMC7699472
OpenAlexW3103776403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.